Civetta is a cancer therapeutics company, founded to advance new medicines through small molecule targeting of beta-propeller domains with the goal of developing important therapeutics for cancers and other diseases.
Civetta’s vision is to develop a broad range of expertise in drugging the propeller domains, spanning from biochemistry to biology to medicinal chemistry.
Civetta Therapeutics was founded in 2019 by William Sellers and Eric Fischer. The company is headquartered in Cambridge, Massachusetts.
Civett takes a comprehensive approach to identify critical propeller protein targets underlying disease and advance therapeutics by creating selective inhibitors or activators.
Civetta Therapeutics is backed by Deerfield Management. The company has raised $53M in a Series A financing on Dec 04, 2019.